5/8/2025

Moderna (NasdaqGS:MRNA) recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1...

Source: Yahoo

5/8/2025

CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ...

Source: Yahoo

5/8/2025

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.

Source: Yahoo

5/8/2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).

Source: Yahoo

5/7/2025

Baillie Gifford's 13F portfolio update: Discover key stake changes in top stocks like Amazon, Tesla & more.

Source: SeekingAlpha

5/7/2025

Forget the Fed. Why Stocks Are Focused on U.S.-China Trade Talks.

Source: MarketWatch

5/7/2025

Flagship Pioneering, the bioplatform innovation company, the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH) and the National University Health System (NUHS) today announced a research and development collaboration to advance outcomes in human health and sustainability. Flagship, NUS Medicine, NUH and NUHS outlined the goals of their collaboration via a Memorandum of Understanding (MOU) signed this week.

Source: Yahoo

5/6/2025

Dr. Vinay Prasad succeeds Dr. Peter Marks, who left the role of leader of the FDA’s Center for Biologics Evaluation and Research in March.

Source: Yahoo

5/6/2025

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

Source: Yahoo

5/6/2025

BioNTech maintains €15.85B reserves as COVID revenues fall and R&D grows.

Source: SeekingAlpha

5/5/2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Source: Yahoo

5/2/2025

Moderna (NasdaqGS:MRNA) recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was relatively flat over the last month. This performance aligns with broader market trends, which saw significant gains due to strong job reports and positive sentiment from potential U.S.-China trade talks. While Moderna's financial results may have added weight to broader market optimism, the stock's minimal...

Source: Yahoo

5/2/2025

The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Source: Yahoo

5/2/2025

CAMBRIDGE - Moderna, Inc. reported financial results and provided business updates for the first quarter of 2025.'In the first quarter, we continued to execute with financial discipline,...

Source: Finnhub

5/2/2025

Moderna reported total revenue of $108m for Q1 2025, down 35% from the same period a year earlier. The decline was primarily due to lower net sales of $86m over the quarter, reflecting lower...

Source: Finnhub

5/2/2025

Despite a significant revenue drop, Moderna Inc (MRNA) focuses on financial discipline and pipeline growth to drive future success.

Source: Yahoo

5/2/2025

Q1 2025 Moderna Inc Earnings Call

Source: Yahoo

5/1/2025

Trims 2026 operating expenses by up to $500M after Q1 revenue plunges 35% to $108M

Source: Yahoo

5/1/2025

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Source: Yahoo

5/1/2025

Moderna's (MRNA) first-quarter loss unexpectedly improved year on year as a drop in expenses helped

Source: Yahoo